Once-Daily Formulation of Galantamine

Journal of the American Medical Directors Association

Volumn 7, Issue 5, 2006, Pages 338-

  Hulihan, Joseph ^a   Spivey, J Michael ^b  

^a Ortho McNeil Pharmaceutical Incorporated   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; DEMENTIA; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG SAFETY; HEALTH CARE FACILITY; HUMAN; LETTER; LONG TERM CARE;

EID: 33744807460     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2006.04.001     Document Type: Letter

References (3)

1. Christensen M.D., and White H.K. Dementia assessment and management. J Am Med Dir Assoc 7 (2006) 109-118
2. RAZADYNE ER/RAZADYNE (galantamine HBr) Extended-Release Capsules and Tablets and Oral Solution Prescribing Information (2005), Ortho-McNeil Neurologics, Inc, Titusville, NJ June
3. Brodaty H., Corey-Bloom J., Potocnik F.C.V., et al. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's Disease. Dement Geriatr Cogn Discord 20 (2005) 120-132